Abstract: Metabolic Syndrome (MS) is a collection of risk factors including insulin resistance, central obesity, hypertension and dyslipidemia and itself is a risk factor for coronary artery disease. In recent times, its prevalence is on a rise in obese children too. Many working criteria for diagnosing MS are doing-the-round; given by World Health Organization, Adult Treatment Panel 3 and American Association of Clinical Endocrinologists. Risk factors involved in the pathogenesis of MS are many-fold; accordingly pharmacotherapy of MS is also multifacet. This review article is an account of pathogenesis, diagnosis and available treatment options in MS with a brief account of future prospect.